Melnikow Joy, McGahan Colleen, Sawaya George F, Ehlen Thomas, Coldman Andrew
Department of Family and Community Medicine, Center for Healthcare Policy and Research, University of California Davis, Sacramento, CA 95817, USA.
J Natl Cancer Inst. 2009 May 20;101(10):721-8. doi: 10.1093/jnci/djp089. Epub 2009 May 12.
Information on the long-term risk of cervical intraepithelial neoplasia (CIN) recurrence among women treated for CIN is limited yet critical for evidence-based surveillance recommendations.
We retrospectively identified 37,142 women treated for CIN 1, 2, or 3 from January 1, 1986, through December 31, 2000 (CIN cohort), from the British Columbia Cancer Agency cytology database and linked their records with cancer registry and vital statistics data. Treatment included cryotherapy, loop electrosurgical excision procedure, cone biopsy, and laser vaporization or excision. A comparison cohort contained 71,213 women with normal cytology and no previous CIN diagnosis. Follow-up continued through December 31, 2004. Among women in both cohorts under active surveillance, we compared rates of CIN 2 or 3 (CIN 2/3) and cervical cancer. Cumulative incidence rates of CIN 2/3 and 95% confidence intervals (CIs) were estimated by a life table approach by using annual rates. Cumulative rates of invasive cancer were examined by the person-years method.
Overall observed cumulative rates of CIN 2/3 in the first 6 years after treatment were 14.0% (95% CI = 13.84% to 14.15%) for women originally treated for CIN 3, 9.3% (95% CI = 9.09% to 9.42%) for CIN 2, and 5.6% (95% CI = 4.91% to 5.21%) for CIN 1. Annual rates of CIN 2/3 were less than 1% after 6 years. Initial diagnosis, age, and treatment type were associated with a diagnosis of CIN 2/3 after treatment, with 6-year adjusted rates for women aged 40-49 years ranging from 2.6% (95% CI = 1.9% to 3.4%) for treatment of CIN 1 with the loop electrosurgical excision procedure to 34.0% (95% CI = 30.9% to 37.1%) for treatment of CIN 3 with cryotherapy. Overall incidence of invasive cancer (per 100,000 woman-years) was higher in the CIN cohort (37 invasive cancers, 95% CI = 30.6 to 42.5 cancers) than in the comparison cohort (six cancers, 95% CI = 4.3 to 7.7 cancers). Cryotherapy, compared with other treatments, was associated with the highest rate of subsequent disease (adjusted odds ratio for invasive cancer = 2.98, 95% CI = 2.09 to 4.60).
Risk of CIN 2/3 after treatment was associated with initial CIN grade, treatment type, and age. Long-term risk of invasive cancer remained higher among women treated for CIN, particularly those treated with cryotherapy.
关于接受宫颈上皮内瘤变(CIN)治疗的女性中CIN复发的长期风险的信息有限,但对于基于证据的监测建议至关重要。
我们从英属哥伦比亚癌症机构细胞学数据库中回顾性地识别出1986年1月1日至2000年12月31日期间接受CIN 1、2或3治疗的37142名女性(CIN队列),并将她们的记录与癌症登记和生命统计数据相链接。治疗方法包括冷冻疗法、环形电切术、锥形活检以及激光汽化或切除术。一个对照队列包含71213名细胞学正常且既往无CIN诊断的女性。随访持续至2004年12月31日。在两个队列中接受主动监测的女性中,我们比较了CIN 2或3(CIN 2/3)以及宫颈癌的发生率。采用生命表法,通过年发生率估计CIN 2/3的累积发生率及95%置信区间(CI)。采用人年法检查浸润性癌的累积发生率。
最初接受CIN 3治疗的女性在治疗后前6年中,CIN 2/3的总体观察累积发生率为14.0%(95%CI = 13.84%至14.15%),CIN 2为9.3%(95%CI = 9.09%至9.42%),CIN 1为5.6%(95%CI = 4.91%至5.21%)。6年后CIN 2/3的年发生率低于1%。初始诊断、年龄和治疗类型与治疗后CIN 2/3的诊断相关,40 - 49岁女性采用环形电切术治疗CIN 1的6年校正发生率为2.6%(95%CI = 1.9%至3.4%),采用冷冻疗法治疗CIN 3的为34.0%(95%CI = 30.9%至37.1%)。CIN队列中浸润性癌的总体发生率(每100000人年)高于对照队列(CIN队列37例浸润性癌,95%CI = 30.6至42.5例癌症;对照队列6例癌症,95%CI = 4.3至7.7例癌症)。与其他治疗方法相比,冷冻疗法与后续疾病的发生率最高相关(浸润性癌的校正优势比 = 2.98,95%CI = 2.09至4.60)。
治疗后CIN 2/3的风险与初始CIN分级、治疗类型和年龄相关。接受CIN治疗的女性中浸润性癌的长期风险仍然较高,尤其是接受冷冻疗法治疗的女性。